title: Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.
abstract: BACKGROUND
  The treatment results of metastatic melanoma are miserable if the tumor has spread beyond the soft tissue and lung, in particular, if dacarbazine (DTIC)-based therapy has failed. Platinum analogs and vinca alkaloids have shown some activity in melanoma. Interleukin-2 (IL-2) may augment the efficacy of chemotherapy.
  
  
  METHODS
  A prospective phase II pilot study was conducted to evaluate the efficacy and tolerability of a regimen which contained carboplatin (450 mg/m(2) on day 1), vinorelbine (30 mg/m(2) on day 1) and IL-2 (9 MU subcutaneously once daily on days 2-5 and 9-12) in metastatic melanoma. Twenty-two patients (11 men, 11 women; median age 56 years) were eligible, of whom 13 had cutaneous, 6 ocular and 3 unknown primary melanoma. Seventeen patients (77%) had liver metastases and an equal number had received prior chemotherapy and/or interferon-alfa for recurrent disease.
  
  
  RESULTS
  One partial response was recorded, yielding a response rate of 4.5% . Nine patients had stable disease for a median of 6.0 months (range 3.0-8.6 months). The median time to progression for all patients was 1.8 months (range 0.7-8.6 months) and the median survival was 7.2 months (range 1.4-42.0 months). Toxicity was moderate but manageable. Myelosuppression was the most significant adverse event.
  
  
  CONCLUSIONS
  This regimen may offer clinical benefit for melanoma patients with poor prognosis as second-line therapy after DTIC has failed.
authors.affiliation: Department of Oncology, Tampere University Hospital, P.O.B 2000, 33521 Tampere, Finland. meri-sisko.vuoristo@fimnet.fi
authors.forename: Meri-Sisko
authors.initials: MS
authors.lastname: Vuoristo
authors.forename: Pia
authors.initials: P
authors.lastname: Vihinen
authors.forename: Tanja
authors.initials: T
authors.lastname: Skyttä
authors.forename: Kristiina
authors.initials: K
authors.lastname: Tyynelä
authors.forename: Pirkko
authors.initials: P
authors.lastname: Kellokumpu-Lehtinen
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D007376:Interleukin-2; D014747:Vinblastine; D016190:Carboplatin; D000077235:Vinorelbine